Archives for Chemistry Experiments of 6684-39-5

There is still a lot of research devoted to this compound(SMILES：ClC1=NC=C(C=C1)[S](=O)(=O)Cl)COA of Formula: C5H3Cl2NO2S, and with the development of science, more effects of this compound(6684-39-5) can be discovered.

So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Wang, Wentian; Zhang, Lu; Morlock, Lorraine; Williams, Noelle S.; Shay, Jerry W.; De Brabander, Jef K. researched the compound: 2-Chloro-5-pyridinesulfonyl chloride( cas:6684-39-5 ).COA of Formula: C5H3Cl2NO2S.They published the article 《Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC)》 about this compound( cas:6684-39-5 ) in Journal of Medicinal Chemistry. Keywords: preparation TASIN analog targeting colorectal cancer. We’ll tell you more about this compound (cas:6684-39-5).

Despite advances in targeted anticancer therapies, there are still no small-mol.-based therapies available that specifically target colorectal cancer (CRC) development and progression, the second leading cause of cancer deaths. We previously disclosed the discovery of truncating adenomatous polyposis coli (APC)-selective inhibitor 1 (TASIN-1), a small mol. that specifically targets colorectal cancer cells lines with truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor gene through inhibition of cholesterol biosynthesis. Here, we report a medicinal chem. evaluation of a collection of TASIN analogs and activity against colon cancer cell lines and an isogenic cell line pair reporting on the status of APC-dependent selectivity. A number of potent and selective analogs were identified, including compounds with good metabolic stability and pharmacokinetic properties. The compounds reported herein represent a first-in-class genotype-selective series that specifically target apc mutations present in the majority of CRC patients and serve as a translational platform toward a targeted therapy for colon cancer.

There is still a lot of research devoted to this compound(SMILES：ClC1=NC=C(C=C1)[S](=O)(=O)Cl)COA of Formula: C5H3Cl2NO2S, and with the development of science, more effects of this compound(6684-39-5) can be discovered.

Reference:
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis—I. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis